TY - JOUR
T1 - Engineered CCR5 superagonist chemokine as adjuvant in anti-tumor DNA vaccination
AU - Dorgham, Karim
AU - Abadie, Valérie
AU - Iga, Mutsunori
AU - Hartley, Oliver
AU - Gorochov, Guy
AU - Combadière, Behazine
N1 - Funding Information:
This work was supported by the French “Agence Nationale de la Recherche” (ANR “jeunes chercheurs” JC05-4645) and Cancéropole Ile-de-France to B.C., the Swiss National Science Foundation (3100A0-11042, O.H.), and the European FP6 “INNOCHEM” and “ATTACK” (Contract: LSHC-CT-2005-018914) programs (G.G.). M.I. was a fellowship recipient of SIDACTION, Paris.
PY - 2008/6/19
Y1 - 2008/6/19
N2 - Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.
AB - Chemokine receptors are promising targets for enhancing T-cell immunity and anti-cancer therapy. CCL5 is a potential adjuvant for DNA vaccination. We postulated that CCR5 superagonists could be even more effective. A CCR5 superagonist derived from natural CCL5 by directed in vitro evolution, namely 1P7, is used as a DNA vaccine adjuvant and expressed as fused chemokine-Ig (1P7-Ig). We show that OVA + 1P7-Ig DNA co-inoculation induced higher frequencies of OVA-specific CD8 lymphocytes than OVA + CCL5-Ig or controls and gave an even better protection against tumor growth in a CCR5-dependant manner. Our results indicate that CCR5-superagonists may provide potent adjuvants for vaccines.
UR - http://www.scopus.com/inward/record.url?scp=44749086303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=44749086303&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2008.04.003
DO - 10.1016/j.vaccine.2008.04.003
M3 - Article
C2 - 18479788
AN - SCOPUS:44749086303
VL - 26
SP - 3252
EP - 3260
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 26
ER -
